OpenNashPodcasts

Topic

Johnson & Johnson

Johnson & Johnson is a large healthcare company, and these podcasts cover its leadership, COVID-19 vaccine work, artificial intelligence and technology plans, and legal and business changes. Speakers include current and former executives, journalists and investors.

Joaquin Duato told Fortune's Leadership Next that Johnson & Johnson has had only eight CEOs in about 130 years, and that he is the first born outside the United States. Alex Gorsky told Mike Milken the company's vaccine uses a vector approach. Andrew Palmer said about 15% of its generative AI projects delivered 85% of the value.

45 facts from 10 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.

More on Johnson & Johnson from OpenNash

1995

In 1995 Amylin partnered with Johnson & Johnson's LifeScan subsidiary, which would share half of development costs and pay all pre-launch marketing costs for pramlintide.

“In that same year, they announced a new partnership with J &J, specifically their subsidiary LifeScan. Under those terms, J &J would share half of the development costs and pay all of the pre-launch marketing costs.”

Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:31:02

1998

In February 1998 Johnson & Johnson ended its partnership with Amylin after pramlintide trial results were weaker in type 2 diabetes than in type 1.

“Since type 2 diabetes is where the real money is at, J &J decides the juice isn't worth the squeeze.”

Alex Kesin · Episode #1: Amylin Pharmaceuticals, 0:32:56

Undated

Seth Klarman bought his first stock, a share of Johnson & Johnson, at about age 10 using birthday money, and it split three for one soon afterward.

“I bought a share of Johnson & Johnson when I was around 10 years old with money I got from my birthday.”

Seth Klarman · Seth Klarman – Timeless Value Investing (EP.328), 0:08:23

Undated

Johnson & Johnson applies AI, machine learning, intelligent automation, data science, analytics and cloud computing to improve processes and efficiency, including accelerating drug discovery in R&D.

“leveraging technologies such as AI, machine learning, intelligent automation, data science, analytics, cloud computing, et cetera, to improve processes, to simplify workflow, to improve efficiencies.”

Rowena Yeo · Episode 12: Rowena Yeo, Chief Technology Officer & Global Vice President, Technology Services at Johnson & Johnson, 0:05:28

Undated

Johnson & Johnson applies criteria to volunteers for its citizen development program, such as data experience and technical aptitude.

“J and J has a s a series of criteria that they apply to you once you volunteer.”

Tom Davenport · Leading a Workforce Empowered by New AI Tools, 0:23:03

Undated

Joaquin Duato said competing with L'Oreal in skincare while also competing in biologics and surgical robotics was too complex for Johnson & Johnson.

“For us, it was very complex to be able to compete with L 'Oreal, as you mentioned, in skincare and at the same time competing biologics with biopharmaceutical companies and in surgical robotics with medical technology companies.”

Joaquin Duato · Janet Yellen on the Current State of the Economy and Joaquin Duato on why J & J is in its "Golden Era", 0:07:34

Undated

Johnson & Johnson moved to a centralized, priority-driven AI approach with a central AI council and a data council.

“they have now pivoted to a much more kind of priority-driven, centralized approach, where, you know, there's a central AI Council”

Andrew Palmer · A Need for Nuance: The Economist’s Andrew Palmer, 0:14:19

Episodes